Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
暂无分享,去创建一个
A. Straube | T. Kraya | C. Gaul | L. Neeb | G. Broessner | X. Hamann | Joachim Hipp
[1] S. Förderreuther,et al. S1-Leitlinie: Therapie der Migräneattacke und Prophylaxe der Migräne , 2023, DGNeurologie.
[2] M. Filippi,et al. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients , 2022, The Journal of Headache and Pain.
[3] H. Diener,et al. Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe , 2022, Der Nervenarzt.
[4] T. Dresler,et al. [Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis]. , 2022, Der Nervenarzt.
[5] T. Hariyanto,et al. Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: A systematic review and meta‐analysis , 2022, Clinical and experimental pharmacology & physiology.
[6] S. Sacco,et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update , 2022, The Journal of Headache and Pain.
[7] J. Mehnert,et al. Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study , 2022, eLife.
[8] R. Ayyagari,et al. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine , 2022, The Journal of Headache and Pain.
[9] R. Ruscheweyh,et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study , 2021, Cephalalgia : an international journal of headache.
[10] C. Kleinschnitz,et al. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience , 2021, The Journal of Headache and Pain.
[11] MD Gil-Sierra,et al. Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series , 2021, European journal of hospital pharmacy : science and practice.
[12] J. Sánchez-Rubio Ferrández,et al. Early Experiences in Switching between Monoclonal Antibodies in Patients with Nonresponsive Migraine in Spain: A Case Series , 2021, European Neurology.
[13] U. Reuter,et al. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis , 2021, CNS Drugs.
[14] H. Ulmer,et al. CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis , 2021, Cephalalgia : an international journal of headache.
[15] T. Taura,et al. Migraine therapeutics differentially modulate the CGRP pathway , 2021, Cephalalgia : an international journal of headache.
[16] D. Friedman,et al. Galcanezumab for the prevention of migraine. , 2020, Pain management.
[17] J. Haan. Faculty Opinions recommendation of Central effects of erenumab in migraine patients: An event-related functional imaging study. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[18] A. May,et al. Non‐Responders to Treatment With Antibodies to the CGRP‐Receptor May Profit From a Switch of Antibody Class , 2019, Headache.
[19] Rongsheng Tong,et al. Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomized clinical trials , 2019, Psychoneuroendocrinology.
[20] H. Diener,et al. Therapie der Migräneattacke und Prophylaxe der Migräne , 2018, Nervenheilkunde.
[21] S. Silberstein,et al. Fremanezumab for the Preventive Treatment of Chronic Migraine , 2017, The New England journal of medicine.
[22] U. Reuter,et al. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies , 2017, Current opinion in neurology.
[23] L. Edvinsson. The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine , 2017, Headache.
[24] Min Yang,et al. Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine , 2011, Cephalalgia : an international journal of headache.
[25] R. Lipton,et al. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers , 2000, Pain.
[26] P. Goadsby,et al. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats , 1993, Annals of neurology.
[27] L. Swanson,et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing , 1983, Nature.
[28] M. Arnold. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition , 2018, Cephalalgia : an international journal of headache.
[29] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..